Alfuzosin Causes the Internal Urethral Sphincter to Relax and Open More Easily
Alfuzosin directly blocks alpha-1 adrenergic receptors in the bladder neck and internal urethral sphincter, causing smooth muscle relaxation that allows the sphincter to open more easily and reduces urethral resistance. This is the fundamental mechanism by which it improves urinary flow in patients with lower urinary tract symptoms.
Mechanism of Action on the Sphincter
Alfuzosin is a selective alpha-1 adrenoreceptor antagonist that specifically targets receptors located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra 1. The smooth muscle tone in these structures is regulated by alpha-adrenergic receptors. When alfuzosin blocks these receptors, it causes the smooth muscle in the bladder neck and internal sphincter to relax, resulting in:
- Decreased urethral pressure - allowing easier opening
- Reduced urethral resistance - less force needed to initiate voiding
- Improved urine flow - direct consequence of easier sphincter opening
- Reduction in BPH symptoms - hesitancy, weak stream, incomplete emptying 1
Evidence of Sphincter Effects
Direct Urethral Pressure Measurements
Research demonstrates alfuzosin's potent effect on reducing urethral pressure:
- In patients with neurogenic bladder dysfunction and high urethral tone, intravenous alfuzosin produced dose-dependent decreases in maximal urethral pressure of 43-46 cm H₂O compared to 23 cm H₂O with placebo 2
- The 2 mg dose was most effective, producing ≥30% decrease in urethral pressure in 69% of patients and ≥50% decrease in 44% of patients 2
- In anesthetized cats, alfuzosin produced dose-related inhibition of urethral pressure increases during sympathetic nerve stimulation 3
Uroselectivity - Preferential Effect on Urethral Sphincter
A critical feature of alfuzosin is its preferential concentration in prostatic tissue compared to plasma:
- Prostatic tissue concentrations were 4.1 times greater than plasma at 1 hour and 8.6 times greater at 6 hours after oral dosing 4
- Effects on urethral pressure correlated strongly with prostate tissue levels (r=0.906), while blood pressure effects correlated with plasma levels (r=0.941) 4
- When administered intraduodenally versus intravenously, alfuzosin showed 10.9-fold greater selectivity for urethral pressure reduction compared to blood pressure effects 5
This uroselectivity means alfuzosin can effectively relax the urethral sphincter at doses that produce minimal cardiovascular effects 3, 6.
Clinical Implications
The sphincter relaxation occurs rapidly - urethral pressure reductions are measurable within hours of administration and are sustained with chronic therapy 2, 4. This translates to:
- Improved ability to initiate voiding (reduced hesitancy)
- Stronger urinary stream
- More complete bladder emptying
- Reduced sensation of obstruction
The effect is present regardless of bladder outlet obstruction grade or bladder contractility, making it effective across a broad spectrum of patients with lower urinary tract symptoms 7.
Important Caveat
While alfuzosin causes the sphincter to open more easily, it does not structurally change prostate size 8. It only addresses the dynamic (functional) component of obstruction by reducing smooth muscle tone, not the static (anatomical) component related to prostate enlargement 1.